Ultrasensitive circulating tumor DNA analysis enables precision medicine: experimental workflow considerations
Open Access
- 4 March 2021
- journal article
- other
- Published by Taylor & Francis in Expert Review of Molecular Diagnostics
- Vol. 21 (3) , 299-310
Abstract
Introduction: Circulating tumor DNA (ctDNA) has become a relevant biomarker in cancer management, allowing tumor assessment through analysis of minimally invasive liquid biopsies. Applications include screening, diagnostics, monitoring of treatment efficacy and detection of minimal residual disease as well as relapse. The potential of ctDNA analysis is significant, but several biological and technical challenges need to be addressed before widespread clinical implementation. Areas covered: Several clinical applications where ctDNA analysis may be beneficial require detection of individual DNA molecules. Consequently, to acquire accurate and informative data the entire workflow from sampling to final data interpretation needs to be optimized. In this review, we discuss the biological and technical challenges of ctDNA analysis and how preanalytical and analytical approaches affect different cancer applications. Expert opinion: While numerous studies have demonstrated the potential of using ctDNA in cancer applications, yet few reports about true clinical utility exist. Despite encouraging data, the sensitivity of ctDNA analyses, i.e. the probability to detect presence of cancer in liquid biopsies, is still an issue. Analysis of multiple mutations in combination with simultaneous assessment of other analytes is one solution. Improved standardization and guidelines will also facilitate the introduction of ctDNA analysis into clinical routine.Keywords
Funding Information
- Assar Gabrielssons Research Foundation (CZ.1.05/1.1.00/02.0109)
- SPIDIA4P (H2020-SC1-HCO-02-2016)
- Swedish Childhood Cancer Foundation (TJ2015-0058, 2020-0007 and MTI2019-0008)
This publication has 162 references indexed in Scilit:
- Influence of Plasma Processing on Recovery and Analysis of Circulating Nucleic AcidsPLOS ONE, 2013
- A New Blood Collection Device Minimizes Cellular DNA Release During Sample Storage and Shipping When Compared to a Standard DeviceJournal of Clinical Laboratory Analysis, 2013
- Increased Death of Adipose Cells, a Path to Release Cell‐Free DNA Into Systemic Circulation of Obese WomenObesity, 2012
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion SequencingNew England Journal of Medicine, 2012
- Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer IDProceedings of the National Academy of Sciences, 2011
- High-Throughput Droplet Digital PCR System for Absolute Quantitation of DNA Copy NumberAnalytical Chemistry, 2011
- Circulating tumour markers can define patients with normal colons, benign polyps, and cancersBritish Journal of Cancer, 2011
- Detection and quantification of rare mutations with massively parallel sequencingProceedings of the National Academy of Sciences, 2011
- Tumour necrosis is a postoperative prognostic marker for pancreatic cancer patients with a high interobserver reproducibility in histological evaluationBritish Journal of Cancer, 2010
- Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylationBritish Journal of Cancer, 2006